MFG
MRNA icon

Mendota Financial Group’s Moderna MRNA Stock Holding History

Mendota Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$67 – 863
2024
Q3 		$67 Sell
1
-9
-90% -$826 ﹤0.01% 1071
2024
Q2 		$1.19K Hold
10
– – ﹤0.01% 296
2024
Q1 		$1.07K Hold
10
– – ﹤0.01% 298
2023
Q4 		$995 Sell
10
-60
-86% -$5.05K ﹤0.01% 335
2023
Q3 		$7.23K Sell
70
-175
-71% -$19.5K 0.01% 208
2023
Q2 		$29.8K Hold
245
– – 0.03% 158
2023
Q1 		$42.2K Hold
245
– – 0.04% 153
2022
Q4 		$44K Buy
+245
New +$40.1K 0.06% 139

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Mendota Financial Group's MRNA Position: Q4 2024 in Review

Mendota Financial Group sold out of Moderna (MRNA) in Q4 2024, closing a stake of 1 share — an estimated $67 sold.

Mendota Financial Group first reported a position in MRNA in Q4 2022 and held it in 8 quarters. The position peaked at $44K in Q4 2022. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Mendota Financial Group reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Mendota Financial Group sold 1 Moderna share in Q4 2024, an estimated $67.
  • Mendota Financial Group first reported a position in Moderna in Q4 2022 and held it in 8 quarters.
  • Mendota Financial Group's Moderna position peaked at $44K in Q4 2022.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Mendota Financial Group's 13F filing for Q4 2024, filed 14 Jan 2025.